Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice

Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice

Background: Patients with high-risk neuroblastoma (NB) have a 5-year event-free survival of less than 50 %, and novel and improved treatment options are needed. Radiolabeled somatostatin analogs (SSTAs) could be a treatment option. The aims of this work were to compare the biodistribution and the th...

Full description

Bibliographic Details
Main Authors: A. Romiani, K. Simonsson, D. Pettersson, A. Al-Awar, N. Rassol, H. Bakr, D.E. Lind, G. Umapathy, J. Spetz, R.H. Palmer, B. Hallberg, K. Helou, E. Forssell-Aronsson
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Heliyon
Subjects:
Lutathera
Radionuclide therapy
High-risk neuroblastoma
Somatostatin analogs
Apoptosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024074401

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024074401

Similar Items